Abbott Unveils Late-Breaking Data Showing The World's First Dual-Chamber Leadless Pacemaker Study Met All Three Primary Safety And Performance Endpoints; To Present On May 19-21 At The Heart Rythm Society Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Abbott announced that its AVEIR DR i2i IDE study, the first prospective study on the safety and performance of the world's first dual-chamber leadless pacemaker, met all three primary safety and performance endpoints. The data has been submitted to the FDA for approval of the AVEIR DR device.
May 20, 2023 | 7:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Abbott's AVEIR DR i2i IDE study met all primary safety and performance endpoints, potentially opening up a new treatment option for people with abnormal heart rhythms.
The successful results of the AVEIR DR i2i IDE study indicate that Abbott's dual-chamber leadless pacemaker is safe and effective, which could lead to FDA approval and expanded treatment options for patients with abnormal heart rhythms. This would likely have a positive impact on Abbott's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100